It is our pleasure to invite you to view the sixth Prostate Cancer Debate to be held in Rome on 23-24 January 2014, supported by the Janssen Pharmaceutical Companies of Johnson & Johnson in Europe.

Recently, a number of therapies have been approved that provide more treatment options and improve outcomes for men with metastatic castration-resistant prostate cancer (CRPC). This debate meeting will provide an opportunity to review the latest data on treatment and the management of patients with metastatic CRPC in daily clinical practice. We have invited international world leaders to join the faculty.

In the first session, we will discuss the topic of personalized medicine, specifically considering how this could be applied to metastatic CRPC. Next, we will consider the mechanisms of action and the possible mechanisms of resistance of the newer agents being approved for metastatic CRPC treatment. We will move through the metastatic CRPC treatment continuum, debating options for patients who have never received chemotherapy, indicators for starting chemotherapy, and treatment options after chemotherapy. Quality of life as an endpoint in both clinical trials and clinical practice will be considered along with pharmacoeconomic considerations driving clinical practice decisions in prostate cancer. Practical considerations in different clinical settings, including the management of elderly and comorbid patients with metastatic CRPC will also be discussed.

Panel discussion sessions are included throughout the program to exchange and share scientific and practical experiences relevant to everyday clinical practice.

We look forward to this Prostate Cancer Debate and hope you will make time to join us for what promises to be a stimulating, educational, and interactive program.